Social Media Ideas for Alnylam Pharmaceuticals

<![CDATA[Pharmaceutical Executive Daily: Alnylam Pharmaceuticals and Inceptive Nucleics Announce 3 Year Strategic Col...

<![CDATA[Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive ]]>

City banks nearly $100M for next-gen RNAi drugs

Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon fol...

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer

Alnylam has partnered with the person who helped put the “T” in ChatGPT, paying $30 million to work with Jakob Uszkoreit’s Inceptive Nucleics on artificial intelligence-enabled dru...

Alnylam, Inceptive ink AI deal potentially worth $2B

The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.

Expansion

Expansion Anonymous (not verified) Mon, 06/29/2026 - 03:04 field_thread_url https://cafepharma.com/boards/threads/expansion.701787/ boar...

Expansion

Expansion Anonymous (not verified) Thu, 06/25/2026 - 03:02 field_thread_url https://cafepharma.com/boards/threads/expansion.701787/ boar...

<![CDATA[Ascidian and Eli Lilly Enter $1.9 Billion Global Research Collaboration to Develop RNA Exon Editors]]>

StockWatch: Positive Phase III Data Sells Investors on Intellia

The data was strong enough for Intellia to continue the rolling Biologics License Application (BLA) submission that it began in April. The company expects to complete the BLA filin...

Amyloidosis Continues To Fight Back

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare H...

Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare H...

Sanofi's Nexviazyme hits primary goal in Pompe disease study

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

AstraZeneca, Ionis drug fails big heart disease study in major setback

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio...

Lilly, Ascidian link up in RNA exon editing pact

Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.

City aims to lay foundation for RNAi renaissance with nearly $100M series B

Looking to spark an antibody-like revolution for RNA interference medicines, City Therapeutics has landed a nearly $100 million series B to fund a clinical push and power further d...

Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class

Intellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatment

Six weeks after Intellia Therapeutics reported that it met its primary endpoint in a phase 3 trial of its in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) for patients...

Nortiva purrs into action with long-acting Lynx platform salvaged from Langer startup

Innoviva has revealed the next steps for Langer Lab assets it rescued from Lyndra Therapeutics’ collapse, launching Nortiva Bio to develop long-acting oral medicines and pursue dru...

Ionis, with new FDA nod, hits a ‘commercial inflection point’

Historically seen as a "platform monetization story," according to one analyst, Ionis now has a potential multibillion-dollar medicine in Tryngolza, which secured expanded approval...